Pollinex Quattro Grass is under clinical development by Allergy Therapeutics and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Pollinex Quattro Grass’s likelihood of approval (LoA) and phase transition for Allergic Rhino-Conjunctivitis took place on 20 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Pollinex Quattro Grass Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Pollinex Quattro Grass overview

Pollinex Quattro Grass is under development for the treatment of grass pollen allergy and seasonal allergic rhino-conjunctivitis (“SAR”). Pollinex Quattro Grass, a subcutaneous vaccine, is a tyrosine-adsorbed glutaraldehyde-modified pollen allergy vaccine containing the new adjuvant monophosphoryl lipid A (MPL). Pollinex Quattro is a group of ultra-short course allergy vaccinations that contain three distinct technologies which act synergistically. The vaccine product development programme involves the exploitation of MPL (Monophosphoryl lipid A), an immunological adjuvant. MPL has demonstrable T helper cell activity and a suitably non-toxic profile. These are combined with a depot technology to provide prolonged desensitization and further improved tolerability. Finally, the immune response is specifically enhanced and directed by an adjuvant MPL.

Allergy Therapeutics overview

Allergy Therapeutics is a specialty pharmaceutical company that develops therapies for allergy treatment and allergy prevention. The company offers a wide range of aluminum-free allergy vaccines and diagnostics. Allergy Therapeutics product portfolio includes Grass Modified Allergen Tyrosine Adsorbed (MATA), Tree MATA, Ragweed MATA, Bee Venom Subcutaneous Immunotherapy (SCIT), and Wasp venom SCIT among others. It also offers allergen extracts used for skin prick testing. The company’s diagnostics products comprise of Pollen, Moulds, Arthropods, Epithelia and others. It has operational presence in Germany, Italy, Spain, Austria, Switzerland, the Netherlands and the UK among others. Allergy Therapeutics is headquartered in Worthing, West Sussex, the UK.

Quick View Pollinex Quattro Grass LOA Data

Report Segments
  • Innovator
Drug Name
  • Pollinex Quattro Grass
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Immunology
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.